First Experiences With The New Testing Examination and Treatment: Methods in Germany: Is This A New Amnog Clone? von Bonduelle, D, Eheberg, D, Plantoer, S

Volltext

Understanding The Role of Subgroup Analysis And Tests For Homogeneity or Interaction in the Amnog Dossier von Hofmann-Xu, L, Bonduelle, D, Eheberg, D

Volltext

Quality Of Life – A Rarely Acknowledged Key Category Within The Amnog Process in Germany von Eheberg, D, Shlaen, R, Batscheider, A, Gohlke, A

Volltext

Fixed Reference Pricing or Benefit Assessment of Established Products – from the Frying Pan into the Fire? von Vosgerau, S, Eheberg, D, Plantör, S, Lebioda, A

Volltext

A Comparison of German Benefit Assessments by G-Ba, IQWiG and Manufacturers von Eheberg, D, Lebioda, A, Hülsebeck, M, Plantör, S

Volltext

Epidemiology and Unmet Medical Need in Diabetes Mellitus Type 2 in Germany –Results of a Literature Search von Greiner, R.A, Paulus, G, Driedger, J, Schröder, C, Timtschenko, V, Batscheider, A, Eheberg, D, Vosgerau, S

Volltext

PHP199 The Impact of the German Pharmaceutical Market Reorganisation Act (AMNOG) on the German Reference Price Market – Trends Two Years After the Introduction of the AMNOG von Eheberg, D, Batscheider, A, Lebioda, A, Plantör, S, Fricke, F.U

Volltext

HTA61 Challenges in Selecting Relevant Comparator Therapies in Indications With Low Evidence Using the Example of German Benefit Assessments With the Appropriate Comparator Therapy... von Mattern, F, Bruns, C, Kovacevic, S, Eheberg, D

Volltext

Methodological Challenges in Comparing Topical Therapies in Dermatology in the Absence of Head to Head Studies von Greiner, R.A, Batscheider, A, Eheberg, D, Gohlke, A, Pfiffner, C, Ehlken, B, Macheleidt, O, Hutt, H.J

Volltext

PUK23 Burden of Chronic Kidney Disease in German Diabetes Patients, a Systematic Literature Review and Data Gap Analysis von Korolewa, V, Hengst, N, Wolff, M, Berger, K, Ehlken, B, Eheberg, D

Volltext

PDG76 IN VITRO DATA AS COMPLEMENTARY EVIDENCE SOURCE FOR THE ASSESSMENT OF ANTIBIOTICS IN THE GERMAN BENEFIT ASSESSMENT? von Mechelke, M., Worf, K., Eheberg, D., Roxlau, T., Bonduelle, D.

Volltext

POSA265 HTA Requirements for Advanced Therapy Medicinal Products (ATMPS) in Germany von Dose, J, Eheberg, D, Hinnenthal, M, Schuh, I, Unterweger, A, Bonduelle, D

Volltext

Quantification Of Patient Preference Analysis: Wearing The Federal Joint Committee Lens To Assess Evidence von Gaba, D, Eheberg, D, Bonduelle, D

Volltext

PHP176 - Quantification Of Patient Preference Analysis: Wearing The Federal Joint Committee Lens To Assess Evidence von Gaba, D, Eheberg, D, Bonduelle, D

Volltext

PMU105 ACCEPTANCE OF EVIDENCE TRANSFER FROM ADULTS TO CHILDREN IN THE CONTEXT OF BENEFIT ASSESSMENT IN GERMANY, FRANCE, AND UK von Weihing, J., Roxlau, T., Bocuk, D., Batscheider, A., Greiner, R.A., Eheberg, D., Bonduelle, D.

Volltext

Differences And Decision Drivers In The Hta-Outcome Category Lower Benefit Between Iqwig And G-Ba Assment In The German Amnog Process von von Hein, M, Jakovac, M, Peters, A, Eheberg, D

Volltext

PHP72 - Differences And Decision Drivers In The Hta-Outcome Category Lower Benefit Between Iqwig And G-Ba Assment In The German Amnog Process von von Hein, M, Jakovac, M, Peters, A, Eheberg, D

Volltext

“Best Supportive Care” or “Therapy According to Physician's Choice” as Appropriate Comparator for German HTA Dossiers – An Underestimated Chance or Risk for the Benefit Assessment?... von Eheberg, D, Dannemann, S, Jakovac, M, Bonduelle, D

Volltext

PHP309 - “Best Supportive Care” or “Therapy According to Physician's Choice” as Appropriate Comparator for German HTA Dossiers – An Underestimated Chance or Risk for the Benefit As... von Eheberg, D, Dannemann, S, Jakovac, M, Bonduelle, D

Volltext

PHP228 - THE IMPACT OF LABEL EXTENSIONS ON THE REIMBURSED PRICE OF PHARMACEUTICAL PRODUCTS ASSESSED ACCORDING TO §35A SGB V IN GERMANY - ONCOLOGICAL AND METABOLIC DISEASES von Schmalhofer, C., Eheberg, D., Tremmel, M., Bocuk, D., Roxlau, T., Antoni, B., Bonduelle, D.

Volltext